Scroll To Top
Health

GlaxoSmithKline to produce Combivir in China

GlaxoSmithKline to produce Combivir in China

We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.

British pharmaceutical company GlaxoSmithKline on Sunday submitted an application to China's State Drug Administration to produce the combination anti-HIV pill Combivir locally in Tianjin, China. If approved, Glaxo will be the first international drugmaker to manufacture an anti-HIV drug in China. The Tianjin plant would be able to start producing Combivir by the end of 2004. The domestically produced medication would cost significantly less than imported versions of the two-drug combination pill, Glaxo officials said. Combivir contains the nucleoside reverse transcriptase inhibitors 3TC and AZT.

Pride of Broadway Special

From our Sponsors

Most Popular

Latest Stories

Advocate.com Editors